Investigational drug · Phase 3
Elebsiran
Also called: VIR-2218, BRII-835
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
5 still active
All registered trials
11
Any phase or sponsor naming "Elebsiran"
First trial start
2021
Jul 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Elebsiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Viral Hepatitis
- Hepatitis D, Chronic
- Chronic Hepatitis B Virus (HBV) Infection
- Hepatitis B, Chronic
- For Treatment of Chronic Hepatitis B Virus Infection
- Chronic Hepatitis B Virus Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Elebsiran" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)Pivotal-lookingRecruiting
Brii Biosciences LimitedIndustry
NCT06650852 · 250 participants (planned) · Start Oct 31, 2024 · Primary completion Sep 2028
Drug: BRII-179; BRII-835 (VIR-2218) and 3 more · For: Chronic Hepatitis B Virus (HBV) Infection
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 14 sites in all
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompleted
Vir Biotechnology, Inc.Industry
NCT04856085 · 244 participants · Start Jul 11, 2021 · Primary completion Mar 16, 2026
Drug: VIR-2218; VIR-3434 and 1 more · For: Hepatitis B, Chronic
Sites: San Francisco, California; Miami, Florida; Orlando, Florida · 37 sites in all
Brii Biosciences LimitedIndustry
NCT06491563 · 150 participants · Start Aug 6, 2024 · Primary completion Aug 5, 2026
Drug: BRII-179; BRII-835 (VIR-2218) and 1 more · For: For Treatment of Chronic Hepatitis B Virus Infection
Sites: Beijing, China; Xiamen, China; Foshan, China · 12 sites in all
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07128550 · 150 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 2026
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Innsbruck, Austria; Vienna, Austria; Bobigny, France · 38 sites in all
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT06903338 · 124 participants · Start Mar 12, 2025 · Primary completion Sep 30, 2026
Drug: Tobevibart; Elebsiran · For: Viral Hepatitis
Sites: Chandler, Arizona; Los Angeles, California; Redwood City, California · 39 sites in all
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07142811 · 100 participants (planned) · Start Aug 5, 2025 · Primary completion Mar 2029
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Brussels, Belgium; Edegem, Belgium; Sofia, Bulgaria · 27 sites in all
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruiting
Vir Biotechnology, Inc.Industry
NCT05461170 · 95 participants · Start Sep 17, 2022 · Primary completion Nov 2031
Drug: VIR-2218; VIR-3434 and 1 more · For: Hepatitis D, Chronic
Sites: Sofia, Bulgaria; Stara Zagora, Bulgaria; Clichy, France · 20 sites in all
Vir Biotechnology, Inc.Industry
NCT04412863 · 84 participants · Start Jul 3, 2020 · Primary completion Mar 25, 2024
Drug: VIR-2218; pegylated interferon-alfa 2a · For: Chronic Hepatitis B
Sites: Birtinya, Australia; Fitzroy, Australia; Hong Kong, Hong Kong · 22 sites in all
Virion TherapeuticsIndustry
NCT06070051 · 35 participants · Start Sep 26, 2023 · Primary completion Mar 31, 2026
Drug: VRON-0200-AdC6; VRON-0200-AdC7 and 2 more · For: Chronic Hepatitis B
Sites: Hong Kong, Hong Kong; Auckland, New Zealand · 3 sites in all
Vir Biotechnology, Inc.Industry
NCT05612581 · 33 participants · Start May 10, 2023 · Primary completion Oct 15, 2024
Drug: VIR-3434; VIR-2218 and 2 more · For: Hepatitis B, Chronic
Sites: Clichy, France; Nice, France; Rennes, France · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure.
Herta T, Gaebler C, Wiegand J, et al. · Semin Liver Dis 2026
- Profile and Predictors of Hepatitis B Surface Antigen Seroreversion Following PEG-IFNα with or Without Therapeutic Vaccine BRII-179 or siRNA Elebsiran: A Post Hoc Pooled Analysis of Two Randomized Controlled Trials in Patients with Chronic Hepatitis B Virus Infection.
Gao Z, Lin B, Wong GL, et al. · Vaccines (Basel) 2026
- Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.
Crespo J, Cabezas J · Transl Gastroenterol Hepatol 2026
- Tobevibart plus elebsiran for the treatment of hepatitis D: how should we read the phase 2 data?
Kushner T, Reau N · Transl Gastroenterol Hepatol 2026
- Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.
Bertoletti A, Ambike SS, Le Bert N, et al. · Antiviral Res 2026
- Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial.
Block PD, Lim JK · Transl Gastroenterol Hepatol 2026
Also in development for Viral Hepatitis
- VIR-3434TobevibartPhase 35 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Hepatitis B, Chronic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.